Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-14-003243
Filing Date
2014-05-14
Accepted
2014-05-14 14:44:25
Documents
13
Period of Report
2014-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0314_dandritbiotech.htm 10-Q 722665
2 LOAN AGREEMENT BY AND BETWEEN DANDRIT DENMARK AND PASECO APS DATED APRIL 29, 201 f10q0314ex10vi_dandritbio.htm EX-10.6 24569
3 LETTER OF SUPPORT OF PASECO APS RELATED TO COMMITTED 2M DKK IN ADDITIONAL FINANC f10q0314ex10vii_dandritbio.htm EX-10.7 4448
4 CERTIFICATION f10q0314ex31i_dandritbio.htm EX-31.1 11772
5 CERTIFICATION f10q0314ex31ii_dandritbio.htm EX-31.2 11816
6 CERTIFICATION f10q0314ex32i_dandritbio.htm EX-32.1 5695
7 CERTIFICATION f10q0314ex32ii_dandritbio.htm EX-32.2 5696
  Complete submission text file 0001213900-14-003243.txt   4617403

Data Files

Seq Description Document Type Size
8 pmhs-20140331.xml EX-101.INS 581813
9 pmhs-20140331.xsd EX-101.SCH 43637
10 pmhs-20140331_cal.xml EX-101.CAL 54277
11 pmhs-20140331_def.xml EX-101.DEF 89337
12 pmhs-20140331_lab.xml EX-101.LAB 341157
13 pmhs-20140331_pre.xml EX-101.PRE 227470
Mailing Address DANDRIT BIOTECH A/S FRUEBJERGVEJ 3 BOX 62 2100 COPENHAGEN G7
Business Address DANDRIT BIOTECH A/S FRUEBJERGVEJ 3 BOX 62 2100 COPENHAGEN G7 45 39179840
DanDrit Biotech USA, Inc. (Filer) CIK: 0001527728 (see all company filings)

EIN.: 452259340 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-54478 | Film No.: 14840867
SIC: 2834 Pharmaceutical Preparations